(1-benzyl-1H-benzoimidazol-2-yl)-guanidine | 41926-58-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: (1-benzyl-1H-benzoimidazol-2-yl)-guanidine
• 英文别名: 1-benzyl-2-guanidinobenzimidazole；1-Benzyl-2-guanidino-benzimidazol；2-(1-Benzylbenzimidazolyl)guanidine；2-(1-benzylbenzimidazol-2-yl)guanidine
• CAS: 41926-58-3
• 化学式: C₁₅H₁₅N₅
• 分子量: 265.318
• InChiKey: YVMNXINHZVYOTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  82.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1-benzyl-1H-benzoimidazol-2-yl)-guanidine 在 盐酸 、 乙二胺 、 sodium nitrite 作用下， 以 戊醇 、 水 为溶剂， 生成 (1-benzyl-1H-benzoimidazol-2-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine
  参考文献：
  名称：

  Anti-hypertensive compositions of benzimidazole derivatives

  摘要：

  抗高血压药物组合物包括式（II）的化合物##SPC1##或其药学上可接受的盐或溶剂，其中R.sub.1是腈或酰胺基；R.sub.2是氢或低碳氢化物；R.sub.3、R.sub.4、R.sub.5和R.sub.6可以相同也可以不同，分别选自氢、卤素、硝基、三氟甲基、低烷基、低酰基、羟基、低醚化羟基或低酰化羟基；以及药学上可接受的载体。式（II）的化合物也可用作合成相应的2-氨基咪唑啉化合物的中间体。

  公开号：

  US03935314A1
• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (1-benzyl-1H-benzoimidazol-2-yl)-guanidine
  参考文献：
  名称：

  Structure activity relationships of human galactokinase inhibitors

  摘要：

  Classic Galactosemia is a rare inborn error of metabolism that is caused by deficiency of galactose-1-phosphate uridyltransferase (GALT), an enzyme within the Leloir pathway that is responsible for the conversion of galactose-1-phosphate (gal-1-p) and UDP-glucose to glucose-1-phosphate and UDPgalactose. This deficiency results in elevated intracellular concentrations of its substrate, gal-1-p, and this increased concentration is believed to be the major pathogenic mechanism in Classic Galactosemia. Galactokinase (GALK) is an upstream enzyme of GALT in the Leloir pathway and is responsible for conversion of galactose and ATP to gal-1-p and ADP. Therefore, it was hypothesized that the identification of a small-molecule inhibitor of human GALK would act to prevent the accumulation of gal-1-p and offer a novel entry therapy for this disorder. Herein we describe a quantitative high-throughput screening campaign that identified a single chemotype that was optimized and validated as a GALK inhibitor. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2014.11.061

文献信息

• US3935314A
  申请人：——

  公开号：US3935314A

  公开（公告）日：1976-01-27
• Anti-hypertensive compositions of benzimidazole derivatives
  申请人：Beecham Group Limited

  公开号：US03935314A1

  公开（公告）日：1976-01-27

  Antihypertensive pharmaceutical compositions comprising a compound of the formula (II) ##SPC1## or pharmaceutically acceptable salts or solvates thereof wherein R.sub.1 is nitrile or amidino; R.sub.2 is hydrogen or lower hydrocarbon; R.sub.3, R.sub.4, R.sub.5 and R.sub.6 which may be the same or different, are each selected from hydrogen, halogen, nitro, trifluoromethyl, lower alkyl, lower acyl, hydroxyl, lower etherified hydroxyl or lower acylated hydroxyl; together with a pharmaceutically acceptable carrier. The compounds of formula (II) are also useful as intermediates in the synthesis of the corresponding 2-aminoimidazoline compounds.

  抗高血压药物组合物包括式（II）的化合物##SPC1##或其药学上可接受的盐或溶剂，其中R.sub.1是腈或酰胺基；R.sub.2是氢或低碳氢化物；R.sub.3、R.sub.4、R.sub.5和R.sub.6可以相同也可以不同，分别选自氢、卤素、硝基、三氟甲基、低烷基、低酰基、羟基、低醚化羟基或低酰化羟基；以及药学上可接受的载体。式（II）的化合物也可用作合成相应的2-氨基咪唑啉化合物的中间体。
• Structure activity relationships of human galactokinase inhibitors
  作者：Li Liu、Manshu Tang、Martin J. Walsh、Kyle R. Brimacombe、Rajan Pragani、Cordelle Tanega、Jason M. Rohde、Heather L. Baker、Elizabeth Fernandez、Burchelle Blackman、James M. Bougie、William H. Leister、Douglas S. Auld、Min Shen、Kent Lai、Matthew B. Boxer

  DOI：10.1016/j.bmcl.2014.11.061

  日期：2015.2

  Classic Galactosemia is a rare inborn error of metabolism that is caused by deficiency of galactose-1-phosphate uridyltransferase (GALT), an enzyme within the Leloir pathway that is responsible for the conversion of galactose-1-phosphate (gal-1-p) and UDP-glucose to glucose-1-phosphate and UDPgalactose. This deficiency results in elevated intracellular concentrations of its substrate, gal-1-p, and this increased concentration is believed to be the major pathogenic mechanism in Classic Galactosemia. Galactokinase (GALK) is an upstream enzyme of GALT in the Leloir pathway and is responsible for conversion of galactose and ATP to gal-1-p and ADP. Therefore, it was hypothesized that the identification of a small-molecule inhibitor of human GALK would act to prevent the accumulation of gal-1-p and offer a novel entry therapy for this disorder. Herein we describe a quantitative high-throughput screening campaign that identified a single chemotype that was optimized and validated as a GALK inhibitor. Published by Elsevier Ltd.